INTRODUCTION
Gluten-sensitive enteropathy (GSE)l (celiac disease, nontropical sprue) is a disease that results in injury to the small intestinal mucosa and is precipitated by the ingestion of wheat gluten and similar proteins in rye, barley, and possibly oats. Exclusion of these proteins from the diet results in clinical and histological improvement. The exact mechanisms causing mucosal damage and subsequent malabsorption are unknown.
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However, several reports suggest that immune mechanisms are important in the pathogenesis of GSE (1) (2) (3) (4) (5) .
The major histocompatibility complex (MHC)-encoded antigens, HLA-B8 and/or -DR3 are found in -65-90% of GSE patients of Northern European origin (6) (7) (8) (9) (10) and linkage studies in families show significant segregation of these antigens with disease (11) . However, 20-30% of subjects in unselected healthy populations carry the same HLA-B8 and/or -DR3 antigens and yet <0.2% of these individuals develop clinical disease (11) . Thus, additional genetic loci or environmental determinants must also influence susceptibility to GSE (12) (13) (14) .
Antibodies to gluten or gliadin can be detected in many GSE patients, but their role, if any, in the pathogenesis of this disease is unknown (15) (16) (17) (18) . We recently reported that antibody responses to gliadin in mice are associated with genes that map to two separate genetic regions; the MHC (H-2) on chromosome 17 and the immunoglobulin heavy chain allotype (IgCH) locus on chromosome 12 (19) .
In this study, we sought to determine whether IgG heavy chain allotype markers (Gm markers) were associated with the production of antibody to gliadin. This report describes a striking association between the IgG2 heavy chain allotype marker G2m(n) and IgG antigliadin antibody (GAb) that was revealed in GSE patients maintained on a gluten-free diet. Sera were typed for IgG (Gm) allotypes using a hemagglutination-inhibition procedure as described before (20, 21) . Notation follows the World Health Organization recommendation on human allotypic markers (22) . Typing was performed for the following allotype markers: Glm(a,x,f), G2m(n), G3m(bO,bl,b3,b5,c3,s,t,g). Because of the lack of a measurable allele, it cannot be determined whether sera having the Gm(f; b) phenotype and IgG2 marker G2m(n) are homozygous or heterozygous for G2m(n). We have used the term G3m(b) to refer to individuals having bO,bl,b3, and b5.
METHODS
All specimens were typed for 13 (1, 2, 3, 4, 5, 6, 7) antigens as described before (20) .
Gliadin. Whole gliadin derived from unbleached flour from bread wheat variety Scout 66 was prepared as follows. 20 g of flour was extracted with 200 ml of 55% ethanol at 40°C for 60 min. After centrifugation at 19,000 g for 10 min, 600 ml of 1.5% NaCI was added to the supernatant to precipitate gliadins from wheat albumins and other nonstorage proteins, and the mixture was centrifuged at 25,000 g for 50 min. The precipitate was washed several times with 1 .5% NaCl, dissolved in 0.01 M acetic acid, dialyzed against H20, and then lyophilized. To remove glutenins and further diminish any albumins that might remain after the precipitation step, the gliadin was further purified by chromatography on Sephadex G-100 using 0.01 M acetic acid, pH 3.2, as eluant. Polyacrylamide gel electrophoresis in pH 3.2 aluminum lactate buffer showed no evidence of albumins moving faster than gliadins, indicating that the preparative approach was effective in separating gliadins from albumins (23, 24 125I-Goat anti-rabbit globulin (GARG) prepared as described previously (25) Fig. 2 . Concentrations of IgG GAb were significantly elevated in patients having G2m(n) regardless of whether the HLA antigens -B8 or -DR3 were present. Although IgG GAb concentrations were initially two-to threefold higher when measured in several GSE patients having G2m(n) before initiation of a gluten-free diet, determinations on serial samples available at two to four intervals over a 2-yr period while on a gluten-free diet indicated that elevated IgG GAb concentrations remained consistently elevated. In two GSE patients having HLA-B8 and -DR3, but lacking G2m(n), sera were available both at the time of diagnosis and at intervals for the subsequent 2 yr. In both patients, GAb levels were elevated at the time of diagnosis (79.5 and 37.0 ;g/ ml), but declined to normal (2.4 and 2.1 Mg/ml) within 6 mo of beginning a gluten-free diet. Table I lists GAb concentrations in our GSE patients and controls according to Gm phenotype. As shown, 22 of 24 GSE patients having the G2m(n) marker had elevated concentrations of IgG GAb, whereas IgG GAb was not increased above control values in any of the six GSE patients lacking G2m(n). Fic.URE 2 Association between IgG GAb and G2m(n) in GSE patients. Subjects are grouped according to whether they are positive or negative for HLA-B8 and/or -DR3 and the IgG heavy chain allotype marker G2m(n). Bars represent the arithmetic mean±SEM, with the number of subjects in each group indicated in brackets. Asterisks indicate statistically significant differences between GSE patients and controls within groups (P < 0.005). All GSE patients were on a glutenfree diet for >18 mo at the time of GAb determination. Not shown, deviation from a gluten-free diet was associated with a transient two-to threefold increase in IgG GAb in two patients having G2m(n) (one patient also had HLA-B8 but not -DR3; one patient lacked both HLA-B8 and -DR3).
Immunoglobulin Allotypes and the
subjects (five with HLA-B8, -DR3, and G2m(n); five with G2m(n) but lacking (P > 0.50).
IgA GAb levels were increased in 14 of 30 GSE patients on a gluten-free diet. Like IgG GAb, GSE patients with increased IgA GAb all had the G2m(n) allotypic marker. Although quantitative levels of serum IgA GAb were not assessed because of the lack of a highly purified IgA antigliadin standard, when expressed as counts per minute of '25I-GARG bound per well, IgG and IgA GAb levels in individual patients correlated significantly (r2 = 0.53; P < 0.005). DISCUSSION Our data demonstrate that IgG GAb are present in 73% of GSE patients maintained on a gluten-free diet for 1.5 to 20 yr. Persistently elevated IgG GAb titers were seen only in GSE patients having the chromosome 14-encoded IgG2 heavy chain allotype marker G2m(n). GAb has been reported in GSE patients before, although prior studies usually used less sensitive assay methods and measured antibody directed to determinants associated with peptic-tryptic digests of gluten or gliadin, or gliadins containing wheat albumins and other impurities (15) (16) (17) (18) (26) (27) (28) (29) (30) . We were fortunate to have a specific, sensitive, and reproducible RIA for GAb (25) and highly purified gliadin (23, 24) .
The finding of persistently increased levels of IgG and, to a lesser extent, IgA GAb in our G2m(n)-positive GSE patients on a gluten-free diet could indicate that these patients are unknowingly ingesting gluten in quantities that are insufficient to activate disease. It seems less likely that the GAb was stimulated by host self-components that cross-react with gluten (i.e., autoimmune), since antibody was present in the absence of active disease and activation of disease required the ingestion of gliadin. This does not exclude the possibility that GAb is involved in mechanisms that damage the small intestine. GAb-mediated injury could be secondary to immune complex deposition in the intestine (i.e., GAb-gliadin immune complexes) (31, 32) GAb was present in 22 of 30 (73%) GSE patients and 0 of 28 controls (P < 0.001). Among GSE patients, GAb was significantly associated with phenotypes having the Gm marker G2m(n) (P < 0.001). t b indicates positive for G3m(bO,1,3,5). § Data expressed as means±1 SE.
K-cell mediated antibody-dependent cytotoxic reactions (33) , with GAb directed to gliadin determinants bound to comrponents of the intestinal mucosa. In this regard, gliadin reportedly binds to reticulin (18, 34) and it has been postulated that GSE patients may have receptors for gliadin on intestinal epithelial cells (4, 13, 35) .
We propose that the striking association between the IgG2 heavy chain allotype marker G2m(n) and GAb in GSE patients on a gluten-free diet reflects the presence of Gmn-linked variable (V)-region genes or Gmn_ linked genes that regulate variable region gene expression. Such V-region genes would encode a variable region on the immunoglobulin heavy chain that in combination with light chains, determines the structure and specificity of GAb (19) . On the basis of this hypothesis, GAb in GSE patients with G2m(n) on a gluten-free diet would be predicted to be of restricted heterogeneity. HLA-B8 and -DR3 positive GSE patients lacking G2m(n) also produced GAb while ingesting gluten. However, such antibody declined rapidly after initiation of a gluten-free diet and, like the GAb noted in some of our Crohn's disease subjects, may differ in its determinant specificity from GAb in GSE subjects having G2m(n). More detailed studies on the characteristics of GAb in these patient groups are currently in progress. This proposal does not exclude the possibility that other IgCH-linked genes on chromosome 14 also could be important in immunoregulation (19) .
HLA-B8 and -DR3 were present in >70% of our GSE patients, a finding noted also in earlier studies (6, 10) . However, the same HLA antigens occur at a high frequency in several organ-specific diseases of presumed autoimmune origin (e.g., autoimmune chronic active hepatitis, myasthenia gravis, Grave's disease, insulin-dependent diabetes mellitus) (36-39). We would suggest that genes that code for HLA-B8 and -DR3 or closely linked genes are common in those diseases because they determine the host response (40) to environmental agents (e.g., viruses) that are critical in the initiation of these otherwise markedly different diseases. Disease susceptibility and organ specificity would be further determined by antigens unique for each disease (e.g., gliadin bound to intestinal mucosal structures in GSE, acetylcholine receptor in myasthenia gravis), the site of antigen encounter and Vregion genes determining antibody specificity. We note that an association between IgCH allotype markers and antiinsulin antibody in insulin-dependent diabetes mellitus (41) , and associations between Gm markers and autoimmune chronic active hepatitis (42), myasthenia gravis (43) , and Grave's disease (44, 45) recently have been described.
We previously reported an association between the Gm phenotype (f;n;b) and GSE in patients lacking HLA-B8 and -DR3 (20) . Thus, both MHC and IgCHlinked genes appear to determine susceptibility to GSE. Athough the effects of MHC genes predominate, in patients lacking HLA-B8 and -DR3 a significant association between IgCH locus markers and GSE can be revealed. Finally, any hypothesis of the pathogenesis of GSE must take into account the fact that HLA-B8, -DR3, and G2m(n) occur in many apparently healthy individuals who do not have clinically evident GSE or GAb. This could suggest that other genes, perhaps coding for a receptor on intestinal mucosal structures that bind gliadin (4, 13) , are necessary for the expression of disease. However, given the lack of complete concordance for GSE in identical twins (6), we favor the additional possibility that an as yet unidentified environmental factor (e.g., a virus) plays a role in initiating GSE.
